Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Standard Dental Labs Inc. Files 2025 Annual Report and Audited Financial Statements 2025 Following Transformational Year and Recent Acquisition Positioning Company for Potential, Significant Revenue Growth

error: Content is protected !!